Barclays Raises Twist Bioscience (NASDAQ:TWST) Price Target to $60.00

Twist Bioscience (NASDAQ:TWST) had its price target upped by Barclays from $45.00 to $60.00 in a research note published on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other research analysts have also issued reports on the stock. Scotiabank increased their target price on shares of Twist Bioscience from $43.00 to $48.00 and gave the stock a sector outperform rating in a research note on Monday, May 6th. Robert W. Baird upped their price target on Twist Bioscience from $39.00 to $40.00 and gave the stock an outperform rating in a research note on Friday, May 3rd. TD Cowen raised their price objective on Twist Bioscience from $55.00 to $65.00 and gave the company a buy rating in a research note on Thursday, June 13th. Guggenheim initiated coverage on Twist Bioscience in a report on Tuesday, June 4th. They set a buy rating and a $53.00 price objective for the company. Finally, Evercore ISI increased their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an outperform rating in a report on Friday, May 3rd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of Buy and an average target price of $48.50.

Twist Bioscience Stock Down 0.7 %

TWST stock opened at $48.93 on Friday. The firm has a market cap of $2.85 billion, a price-to-earnings ratio of -14.56 and a beta of 1.78. The company’s fifty day simple moving average is $44.23 and its 200 day simple moving average is $38.49. Twist Bioscience has a 12-month low of $14.42 and a 12-month high of $55.26.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. The company had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The firm’s revenue was up 25.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.06) EPS. Research analysts expect that Twist Bioscience will post -3.08 earnings per share for the current year.

Insider Buying and Selling

In other Twist Bioscience news, COO Patrick John Finn sold 2,174 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total value of $65,480.88. Following the transaction, the chief operating officer now directly owns 176,206 shares in the company, valued at $5,307,324.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Twist Bioscience news, COO Patrick John Finn sold 2,174 shares of the business’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total value of $65,480.88. Following the sale, the chief operating officer now directly owns 176,206 shares in the company, valued at $5,307,324.72. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Emily M. Leproust sold 4,163 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $154,572.19. Following the transaction, the chief executive officer now directly owns 509,986 shares in the company, valued at approximately $18,935,780.18. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,246 shares of company stock valued at $706,593. 3.92% of the stock is owned by insiders.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently modified their holdings of the business. Artisan Partners Limited Partnership boosted its holdings in Twist Bioscience by 111.3% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after buying an additional 1,961,621 shares during the period. Invesco Ltd. raised its holdings in Twist Bioscience by 1,496.2% during the 3rd quarter. Invesco Ltd. now owns 831,006 shares of the company’s stock valued at $16,836,000 after acquiring an additional 778,944 shares during the period. ARK Investment Management LLC raised its holdings in Twist Bioscience by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after acquiring an additional 427,274 shares during the period. AEGON ASSET MANAGEMENT UK Plc bought a new stake in Twist Bioscience during the 4th quarter valued at $11,956,000. Finally, Norges Bank bought a new stake in Twist Bioscience during the 4th quarter valued at $10,766,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.